Angiotensin-II biochemistry and physiology: Update on Angiotensin-II receptor blockers

Cardiovascular Drug Reviews

Volumn 15, Issue 1, 1997, Pages 75-100

  Bermann, Martin A ^a   Walsh, Mary F ^a   Sowers, James R ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II receptor; Angiotensin II receptor blockers; Blood pressure; Losartan; Renin angiotensin aldosterone system; Vasoconstriction; Volume regulation

Indexed keywords

2 ETHYL 4 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHOXY]QUINOLINE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ENALAPRIL; GLUCOSE; GLUCOSE TRANSPORTER; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN;

ALDOSTERONE RELEASE; ANGIONEUROTIC EDEMA; ANIMAL BEHAVIOR; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG EFFICACY; GLUCOSE METABOLISM; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; LIVER METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; OVULATION; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; UTERUS GROWTH; VASCULARIZATION; VASOCONSTRICTION;

EID: 0030829360     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1997.tb00325.x     Document Type: Review

References (271)

1. Aguilera G. Role of angiotensin II receptor subtypes in the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat. Mol Cell Endocrinol 1992;90:53-60.
2. Alexander RW, Brock TA, Gimbrone MA Jr, Rittenhouse SE. Angiotensin increases inositol trisphosphate and calcium in vascular smooth muscle. Hypertension 1985;7:447-451.
3. Anderson GH Jr, Streeten DH, Dalakos TG. Pressor response to 1-sar-8-ala angiotensin II (saralasin) in hypertensive subjects. Circ Res 1977;40:243-250.
4. Aumelas A, Sakarellos C, Lintner K, et al. Studies on angiotensin II and analogs: Impact of substitutions in position 8 on conformation and activity. Proc Natl Acad Sci USA 1985;82:1991-1995.
5. Azuma H, Hamasaki H, Niimi Y. Prevention of intimai thickening after endothelial removal by a non-peptide angiotensin II receptor antagonist losartan. Br J Pharmacol 1992;106:665-671.
6. Balla T, Baukal AJ, Eng S, Catt KJ. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla. Mol Pharmacol 1991;40:401-406.
7. Ballermann BJ, Skorecki KL, Brenner BM. Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am J Physiol 1984;247:F110-F116.
8. Barker S, Marchant W, Clark AJL, et al. Comparison of COS cell transfected AT1A and AT1B angiotensin II receptors and angiotensin II receptor isoforms in rat tissues using isoelectric focusing. Biochem Biophys Res Commun 1993;192:392-398.
9. Batin P. Gardiner SM, Compton AM, Bennett T. Differential regional haemodynamic effects of the nonpeptide angiotensin II antagonist, DuP753, in water replete and water deprived Brattleboro rats. Life Sci 1991;48:733-739.
10. Batin P, Gardiner SM, Compton AM, Kemp PA, Bennett T. Cardiac haemodynamic effects of the non-peptide angiotensin II antagonist, DuP753 in conscious Long Evans and Brattieboro rats. Br J Pharmacol 1991;103:1585-1591.
11. Bellucci A, Wilkes BM. Mechanism of sodium modulation of glomerular angiotensin receptors in the rat. J Clin Invest 1984;74:1593-1600.
12. Belz GG, DeMey, C Schroeter V, Li Q. Effects of losartan and enalapril on the in situ venoconstrictor responses to angiotensin I and angiotensin II in healthy man. Clin Pharmacol Ther 1993;53(2):139.
13. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: A new activity for platelet derived growth factor. Science 1986;232:87-90.
14. + exchange in cultured vascular smooth muscle cells. J Biol Chem 1987;262:5057-5064.
15. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-314.
16. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis 1993;22:745-754.
17. Bhat GJ, Thekkumkara TJ, Thomas WG, Conrad KM, Baker KM. Angiotensin II stimulates sis inducing factor like DNA binding activity. J Biol Chem 1994;269:31443-31449.
18. Bihoreau C, Monnot C, Davies E, et al. Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G protein coupling. Proc Natl Acad Sci USA 1993;90:5133-5137.
19. Bing C, Johnson IR, Pipkin FB. Angiotensin receptors in myometrium and myometrial vessels from uteri of women during the follicular and luteal phases of the menstrual cycle and in late pregnancy. Clinical Science 1996;90(6):499-505.
20. Binkley PF, Haas GJ, Maymir JC, Brown DM, Cody RJ. Angiotensin II blockade promotes increased conduit vessel compliance in the spontaneously hypertensive rat (SHR). Joint meeting, Association of American Physicians, American Society for Clinical investigation, and American Federation for Clinical Research: Seattle, WA, May 3-6, 1991 Clin Res 1991;39:231A.
21. Bird IM, Hanley NA, Word RA, et al. Human NCI H295 adrenocortical carcinoma cells: A model for angiotensin II responsive aldosterone secretion. Endocrinology 1993;133:1555-1561.
22. Blankley CJ, Hodges JC, Klutchko SR, Himmelsbach RJ, et al. Synthesis and structure activity relationships of a novel series of non peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J Med Chem 1991;34:3248-3260.
23. Bottari SP, de Gasparo M, Steckelings M, Levens NR. Angiotensin II receptor subtypes, characterization, signaling mechanisms, and possible physiological implications. Front Neuroendocrinol 1993;14:123-171.
24. Braszko J. The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Acta Neurobiologiae Experimentalis 1996;56:49-54.
25. Braun Menendez E, Fasciolo JC, Leloir LF, Munoz JM. La substancia hipertensora de la sangre del rinon isquemiado. Rev Soc Argent Biol 1939;15:420-425.
26. Braun Menendez E, Page IH. Suggested revision of nomenclature: Angiotensin. Science 1958;127:242.
27. Bright R. Tabular view of the morbid appearances in 100 cases connected with albuminous urine: with observations. Guy's Hosp Rep 1836;1:380-400.
28. Brock TA, Alexander RW, Ekstein LS, Atkinson WJ, Gimbrone MA Jr. Angiotensin increases cytosolic free calcium in cultured vascular smooth muscle cells. Hypertension 1985;7:I105-I109.
29. + pump activity in cultures of smooth muscle from rat aorta. Proc Natl Acad Sci USA 1982;79:1438-1442.
30. + transport in cultured aortic smooth muscle and brain microvessel cells. In: Acton RT, Lynn JD, eds. Eucaryotic cell cultures: Basics and applications. New York: Plenum. 1984:435-454.
31. Brown GP, Douglas JG, Krontiris Litowitz J. Properties of angiotensin II receptors of isolated rat glomeruli: Factors influencing binding affinity and comparative binding of angiotensin analogs. Endocrinology 1980;106:1923-1929.
32. Brown GP, Douglas JG. Angiotensin n binding sites in rat and primate isolated renal tubular basolateral membranes. Endocrinology 1983;112:2007-2014.
33. Brown GP, Douglas JG. Angiotensin II binding sites on isolated rat renal brush border membranes. Endocrinology 1982;111:1830-1836.
34. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors. Hypertension 1991;17: 720-721.
35. Bumpus FM, Khosla MC. Angiotensin analogs as determinants of the physiologic role of angiotensin and its metabolites. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: Physiopathology and Treatment. New York: McGraw Hill, 1976:183-201.
36. Burnier M, Rutschmann B, Nussberger J, et al. Salt dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-347.
37. Cadena DL, Gill GN. Receptor tyrosine kinases. FASEB J 1992;6:2332-2337.
38. Calcagnetti DJ, Schechter MD. Calcium channel blockade attenuates angiotensin II induced drinking in rats. Brain Res Bull 1993;30:593-596.
39. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest 1986;78:31-39.
40. Capponi AM, Lew PD, Vallotton MB. Cytosolic free calcium levels in monolayers of cultured rat aortic smooth muscle cells. J Biol Chem 1982;260:7836-7842.
41. 2+ and aldosterone production in bovine adrenal glomerulosa cells. Evidence for a difference in the mode of action of angiotensin II and potassium. J Biol Chem 1984;259:8863-8869.
42. Caputo FA, Rowland NE, Fregly MJ. Angiotensin related intakes of water and NaCl in Fischer 344 and Sprague Dawley rats. Am J Physiol 1992;262:R382-R388.
43. Case DB, Wallace HM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med 1976;60:825-836.
44. Chan DP, Sandok EK, Aarhus LL, Heublein DM, Burness JC Jr. Renal specific actions of angiotensin II receptor antagonism in the anesthetized dog. Am J Hypertens 1992;5:354-360.
45. Chan JCN, Critchley JAJH, Cockram CS, et al. Antihypertensive and antialbuminuric effects of losartan potassium and felodipine ER in elderly hypertensive Chinese with/without NlDDM. J Hypenens (in press).
46. Chiou CY, Kifor I, Moore TJ, Williams GH. The effect of losartan on potassium stimulated aldosterone secretion in vitro. Endocrinology 1994;134:2371-2375.
47. Chiu AT, Carini DJ, Johnson AJL, et al. Nonpeptide angiotensin II receptor antagonists. II: Pharmacology of S 8308. Eur J Pharmacol 1988;157:13-21.
48. Chiu AT, Herblin WF, McCall DE, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989;165:196-203.
49. Chiu AT, McCall DE, Price WA, et al. In vitro pharmacology of DuP753. Am J Hypertens 1991;4:282S-295S.
50. Christen Y, Waeber B, Nussberger J, et al. Dose response relationships following oral administration of DuP753 to normal humans. Am J Hypertens 1991;4(2):350-353.
51. Christen Y, Waeber B, Nussberger J, Le RJ, Timmermans PBMWM, Brunner HR. Dose response relationship following oral administration of DuP753 to normal humans. Am J Hypertens 1991;4:271S-272S.
52. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP753 a specific angiotensin II receptor antagonist to normal male volunteers: Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991;83:1333-1342.
53. Clark KL, Robertson MJ, Drew GM. Role of angiotensin AT1 and AT2 receptors in mediating the renal effects of angiotensin II in the anaesthetized dog. Br J Pharmacol 1993;109:148-156.
54. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993;22:579-584.
55. Cody RJ, Haas GJ, Binkley PF, Brown DM. Hemodynamic and vascular characteristics of DuP753 a specific angiotensin II antagonist in the spontaneously hypertensive rat (SHR). J Am Coll Cardiol (Suppl 2A) 1991;17:202A.
56. Cozza EN, Gomez Sanchez CE. Mechanisms of ET 1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol 1993;265:E179-E183.
57. Crozier I, Ikram H, Awan N, et al (Losartan Hemodynamic Study Group). Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 1995;91:691-697.
58. Darnell JEJ, Kerr IM, Stark GR. Jak STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
59. Davies MG, Fulton GJ, Barber L, Dalen H, Svendsen E, Hagen PO. Characterisation of angiotensin II receptor mediated responses and inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor, L158,809. Eur J Vasc Endovasc Surg 1996;12:151-161.
60. de Simone G, Devereux RB, Camargo MJ, Wallerson DC, Sealey JE, Laragh JH. Reduction of development of left ventricular hypertrophy in salt loaded Dahl salt sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996;9:216-222.
61. DeGasparo M, Bottari S, Leven NR. Characteristics of angiotensin II receptors and their role in cell and organ physiology. In: JH Laragh, BM Brenner, eds. Hypertension: Pathophysiology, Diagnosis, and Management 2nd ed. New York: Raven Press. 1995:1695-1720.
62. Desarnaud F, Marie J, Lombard C, et al. Deglycosylation and fragmentation of purified rat liver angiotensin II receptor: Application to the mapping of hormone binding domains. Biochem J 1993;289:289-297.
63. Dickstein K, Gottlieb S, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994;12(2 suppl):S31-S35.
64. Douglas J, Goldner GA, Hopfer U. Angiotensin inhibits and stimulates cyclic AMP production of rabbit proximal tubular epithelial cells. Clin Res 1986;34:696A.
65. Douglas JG, Khosla MC, Bumpus FM. Efficacy of octa and heptapeptide antagonists of angiotensin II as inhibitors of ATIII in the rat adrenal glomerulosa. Endocrinology 1985;116:1698-1702.
66. Douglas JG, Michailov M, Khosla MC, Bumpus FM. Comparative studies of receptor binding and steroidogenic properties of angiotensin in rat adrenal glomerulosa. Endocrinology 1979;104:71-75.
67. Douglas JG, Michailov M, Khosla MC, Bumpus FM. Comparative receptor binding properties of heptapeptide and octapeptide antagonists of angiotensin II in rat adrenal glomerulosa and uterine smooth muscle. Endocrinology 1980;106:120-124.
68. Duff JL, Berk BC, Corson MA. Angiotensin II stimulates the pp44 and pp42 mitogen activated protein kinases in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 1992;188:257-264.
69. Duff JL, Monia BP, Berk BC. Mitogen activated protein (MAP) kinase is regulated by the MAP kinase phosphatase (MKP 1) in vascular smooth muscle cells. J Biol Chem 1995;270:7161-7166.
70. Dzau VJ. Short and long term determinants of cardiovascular function and therapy: Contributions of circulation and tissue renin angiotensin systems. J Cardiovasc Pharmacol 1989;14:51-55.
71. α2A adrenergic receptor. J Biol Chem 1995;270:4681-4688.
72. Eberhardt RT, Kevak RM, Kang PM, et al. Angiotensin II receptor blockade: An innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993;33:1023-1038.
73. Edwards RM, Trizna W, Stack EJ, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush border membranes. J Pharmacol Exp Ther 1996;276: 125-129.
74. Eggena P, Krall JF, Eggena MP, Clegg K, Fittigoff M, Barrett JD. Production of angiotensinogen in rat aortic smooth muscle cells. In: Clin Exp Hypertens - Part A, Theory & Practice. 1990;12:1175-1189.
75. Elton TS, Stephan CC, Taylor GR, et al. Isolation of two distinct type I angiotension II receptor genes. Biochem Biophys Res Commun 1992;184:1067-1073.
76. Ernsberger P, Zhou J, Damon TH, Douglas JG. Angiotensin II receptor subtypes in cultured rat renal mesangial cells. Am J Physiol 1992;263:F411-F416.
77. Fasciolo JC. The experimental observation that led to the discovery of angiotensin. Hypertension 1990; 16:194-198.
78. Fenoy FJ, Milicic L, Smith RD, Wong PC, Timmermans PBMWM, Roman RJ. Effects of DuP753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens 1991;4:321S-326S.
79. Ferrario CM, Barnes KL, Block CH, et al. Pathways of angiotensin formation and function in the brain. Hypertension (Suppl 2) 1990;15:113-119.
80. Ferrario CM, Santos RAS, Brosnihan KB, et al. A hypothesis regarding the function of angiotensin peptides in the brain. Clin Exp Hypertens [A] 1988;10(suppl 1):107-121.
81. Fontoura BMA, Nussenzveig DR, Timmermans PBMWM, Maack T. DuP753 is a potent antagonist of angiotensin II receptors in isolated perfused rat kidney and in cultured renal cells. Am J Hypertens 1991;4(pt 2):303S-308S.
82. Frederich PC Jr, Kahn BB, Peach MJ, Flier JS. Tissue specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992;19:339-344.
83. Gallo Payet N, Chouinard L, Balestre MN, Guillon G. Involvement of protein kinase C in the coupling between the V1 vasopressin receptor and phospholipase C in rat glomerulosa cells: Effects on aldosterone secretion. Endocrinology 1991;129:623-634.
84. Gansevoort RT dD, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin angiotensin system? Kidney Int 1994;45(3):861-867.
85. Garwitz ET, Jones AW. Aldosterone infusion into the rat and dose dependent changes in blood pressure and arterial ionic transport. Hypertension 1982;4:374-381.
86. 125I angiotensin II binding sites in the rat and dog kidney. Peptides 1984;5:1043-1048.
87. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy not hyperplasia of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-756.
88. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure plasma renin activity and angiotensin II in volunteers. Hypertension 1993;21:704-713.
89. Goldberg MR, de Mey C, Wroblewski JM, Li Q, Schroeter V, Belz GG. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Clin Pharmacol Ther 1996;59:72-82.
90. Gonzalez Espinosa C, Garcia Sainz JA. Angiotensin II and active phorbol esters induce proto oncogene expression in isolated rat hepatocytes. Biochim Biophys Acta 1991;1136:308-314.
91. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized placebo controlled double blind parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-1350.
92. Griendling KK, Berk BC, Ganz P, Gimbrone MA Jr, Alexander RW. Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the an lecture. Hypertension 1987;9:111181-111185.
93. Griendling KK, Delafontaine P, Rittenhouse SE, Gimbrone MA Jr, Alexander RW. Correlation of receptor sequestration with sustained diacylglycerol accumulation in angiotensin II stimulated cultured vascular smooth muscle cells. J Biol Chem 1987;262:14555-14562.
94. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MAJ, Alexander RW. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II stimulated vascular smooth muscle cells. J Biol Chem 1986;261:5901-5906.
95. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle. J Cardiovasc Pharmacol 1989;14:527-333.
96. Gunther S. Characterization of angiotensin receptor subtypes in rat liver. J Biol Chem 1984;259:7622-7629.
97. Gutkind JS, Kurihara M, Castren E, Saavedra JM. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. J Hypertens 1988;6:79-84.
98. Gutkind JS, Kurihara M, Saavedra JM. Increased angiotensin II receptors in brain nuclei of DOCA salt hypertensive rats. Am J Physiol 1988;255:H646-H650.
99. Hahn AWA, Jonas U, Buhler FR, Resink TJ. Identification of a fourth angiotensin AT1 receptor subtype in rat. Biochem Biophys Res Commun 1993;192:1260-1265.
100. Hajnoczky G, Csordas G, Bago A, Chiu AT, Spat A. Angiotensin II exerts its effect on aldosterone production and potassium permeability through receptor subtype AT1 in rat adrenal glomerulosa cells. Biochem Pharmacol 1992;43:1009-1012.
101. Hall JE. Control of blood pressure by the renin angiotensin aldosterone system. Clin Cardiol (Suppl IV) 1991;14:6-21.
102. Hatch M, Freel RW, Shahinfar S, Vaziri ND. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. J Pharmacol Exp Ther 1996;276:187-193.
103. 2 adrenergic receptor are involved in distinct pathways of receptor desensitization. J Biol Chem 1989;264:12657-12665.
104. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type 2 receptor gene in mice. Nature 1995;377:744-747.
105. Helmer OM. Differentiation between two forms of angiotonin by means of spirally cut strips of rabbit aorta. Amer J Physiol 1957;188:571-577.
106. Hilgers KF, Mann JFL. Tissue renin: Focus on vascular angiotensin formation. Arzneimittelforschung 1993;43:198-201.
107. Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW. Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J Biol Chem 1994;269:30953-30959.
108. Hogarty DC, Phillips MI. Vasopressin release by central angiotensin II is mediated through an angiotensin type 1 receptor and the drinking response is mediated by both AT 1 and AT 2 receptors. Soc Neurosci Abstr 1991;17:1188.
109. Hogarty DC, Speakman EA, Puig V, Phillips MI. The role of angiotensin AT 1 receptor and AT 2 receptors in the pressor, drinking and vasopressin responses to central angiotensin. Brain Res 1992;586:289-294.
110. Hohle S, Culman J, Boser M, Qadri F, Unger T. Effect of angiotensin AT2 and muscarinic receptor blockade on osmotically induced vasopressin release. Europ J Pharmacol 1996;300:119-123.
111. Huckle WR, Dy RC, Earp HS. Calcium dependent increase in tyrosine kinase activity stimulated by angiotensin II. Proc Natl Acad Sci USA 1992;89:8837-8841.
112. Huckle WR, Prokop CA, Dy RC, Herman B, Earp S. Angiotensin II stimulates protein tyrosine phosphorylation m a calcium dependent manner. Mol Cell Biol 1990;10:6290-6298.
113. Huckle WR, Drag MD, Acker WR, et al. Effects of subtype selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation 1996;93:1009-1019.
114. Hug H, Sarre TF. Protein kinase C isoenzymes: Divergence in signal transduction? Biochem J 1993;291: 329-343.
115. Hunyady L, Baukal AJ, Balla T, Catt KJ. Independence of type I angiotensin II receptor endocytosis from G protein coupling and signal transduction. J Biol Chem 1994;269:24798-24804.
116. Hunyady L, Bor M, Balla T, Catt KJ. Critical role of a conserved intramembrane tyrosine residue in angiotensin II receptor activation. J Biol Chem 1995;270:9702-9705.
117. Husain A, DeSilva P, Speth RC, Bumpus FM. Regulation of angiotensin II in rat adrenal glands. Circ Res 1987;60-640-648.
118. Ichiki T, Labosky PA, Shiota C, Okuyama S, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type 2 receptor. Naiure 1995;377:748-750.
119. Ideishi M, Noda K, Sasaguri M, Ikeda M, Arakawa K. Angiotensin II forming activity of vascular endothelial and smooth muscle cells. Artery 1993;20:95-102.
120. Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994;19:222-227.
121. Inasami T, Guo DF, Kitami Y. Molecular biology of angiotensin n receptors: An overview. J Hypertens (Suppl 10) 1994;12:S83-S94.
122. Inagami T, Mizuno K, Naruse M, et al. Active and inactive renin in the adrenal. Am J Hypertens 1989;2:311-319.
123. Ishida Y, Kawahara Y, Tsuda T, Yokoyama M. Involvement of MAP kinase activators in angiotensin II induced activation of MAP kinases in cultured vascular smooth muscle cells. FEBS Lett 1992;310:41-45.
124. Iwai N, Inasami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992;298:257-260.
125. Ji H, Leung M, Zhang Y, Catt KJ, Sandberg K. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. J Biol Chem 1994;269:16533-16536.
126. 2+ concentration changes evoked by angiotensin II and vasopressin in individual rat aortic smooth muscle cells. Use of microfluorometry and digital imaging. J Biol Chem 1991;266:12618-12626.
127. Johnston CI FB, Jandeleit K. Intrarenal rerun angiotensin system in renal physiology and pathophysiology. Kidney Int (Suppl) 1993;42:359-63.
128. Jover B, Dupont M, Nafialdi E, Mimran A. Effect of the angiotensin antagonist DuP753 on the renal adaptation to sodium restriction in the rat. J Hypertens (Suppl 6) 1991;9:210S-211S.
129. Kai H, Griendling KK, Lassegue B, Ollerenshaw JD, Runge MS, Alexander RW. Agonist induced phosphorylation of the vascular type I angiotensin II receptor. Hypertension 1994;24:523-527.
130. Kakar SS, Riel KK, Neill JD. Differential expression of ATII receptors subtype mRNA's (AT 1A and AT 1B) in the brain. Biochem Biophys Res Commun 1992;185:688-692.
131. Kambayashi Y, Bardhan S, Takahashi K, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993;268:24543-24546.
132. Kanagy NL, Pawloski CM, Fink GD. Role of aldosterone in angiotensin II induced hypertension in rats. Am J Physiol 1990;259:R102-R109.
133. Kauffman RJ, Bean JS, Zimmerman KM, Brown RF, Steinberg MI. Losartan a non peptide angiotensin II (ANGII) receptor antagonist inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 1991;49:PL223-PL228
134. Keiser JA, Bjork FA, Hodges JC, Taylor DG Jr. Renal hemodynamic and excretory responses to PD 123319 and losartan nonpepude AT1 and AT2 subtype specific angiotensin II ligands. J Pharmacol Exp Ther 1992;262:1154-1160.
135. Khosla MC, Smeby RR, Bumpus FM. Structure activity relationship in angiotensin II analogs. In: Page IH, Bumpus FM, eds. Angiotensin, Berlin: Springer Verlag, 1974:126-161.
136. Kifor I, Dzau VJ. Endothelial renin angiotensin pathway: Evidence for intracellular synthesis and secretion of angiotensins. Circ Res 1987;60:422-428.
137. Kinami Y, Ohura T, Marumoto K, Wakamiya K, Hiwarke K. Differential gene expression and regulation of type 1 ATII receptor subtypes in the rat. Biochem Biophys Res Commun 1992;188:446-452.
138. Kirby RF, Thunhorst RL, Johnson AK. Effects of a non peptide angiotensin receptor antagonist on drinking and blood pressure responses to centrally administered angiotensins in the rat. Brain Res 1992;576:348-350.
139. Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long term mortality in severe congestive heart failure. Am J Cardiol 1992;69:103-107.
140. Kohlstaedt KG, Helmer OM, Page IH. Activation of renin by blood colloids. Proc Soc Exp Biol Med 1938;39:214-215.
141. 2+ efflux and aldosterone production in adrenal glomerulosa cells. Am J Physiol 1985;248:E36-E43.
142. Kono T, Koso Y, Khosla MC, Sakura N. Tyrosine in position 4 is the key amino acid for binding of angiotensin II to human arteriolar receptor. Endocrinol Jpn 1987;34:737-743.
143. Kubo A, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996;27:58-63.
144. Kwatra MM, Leung E, Maan AC, et al. Correlation of agonist induced phosphorylation of chick heart muscarinic receptors with receptor desensitization. J Biol Chem 1987;262:16314-16321.
145. Lantelme P, Lo M, Mullins JJ, Gharib C, Bizollon CA, Sassard J. Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats. J Cardiovasc Pharmacol 1996;27:476-481.
146. Lassegue B, Alexander RW, Clark M, Akers M, Griendling KK. Phosphatidylcholine is a major source of phosphatidic acid and diacylglycerol in angiotensin II stimulated vascular smooth muscle cells. Biochem J 1993;292:509-517.
147. Lefkowitz RJ. G protein coupled receptor kinases. Cell 1993;74:409-412.
148. Leung KH, Roscoe WA, Smith RD, Timmermans PBMWM, Chiu AT. Characterization of biochemical responses of angiotensin II (AT2) binding site in the rat pheochromocytoma PC12W cells. Eur J Pharmacol 1992;227:63-70.
149. Leung KH, Smith RD, Timmermans PBMWM, Chiu AT. Regional distribution of the two subtypes of angiotensin II receptor in rat brain using selective nonpeptide antagonists. Neurosci Lett 1991;123:95-98.
150. Levens NR, de Gasparo M, Wood JM, Bottari SP. Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? Pharmacol Toxicol 1992;71:241-249.
151. Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2 subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996;98:418-425.
152. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (Collaborative Study Group). The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
153. Li T, Zimmerman BG. Hemodynamic effect of a novel nonpeptide angiotensin II receptor antagonist DuP753 in the rabbit. J Hypertens (Suppl 3) 1990;8:S97.
154. Li XC, Widdop RE. Angiotensin type I receptor antagonists CV 11974 and EXP 3174 cause selective renal vasodilatation in conscious spontaneously hypertensive rats. Clin Sci 1996;91:147-154.
155. α2a adrenergic receptor confer short term agonist promoted desensitization. Evidence for a receptor kinase mediated mechanism. J Biol Chem 1992;267:4740-4746.
156. Loutzenhiser R, Epstein M, Hayashi K, Takenaka T, Forster H. Characterization of the renal microvascular effects of angiotensin II antagonist DuP753: Studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 1991;4:309S-314S.
157. Macari D, Bottari S, Whitebred S, DiGasparo M, Levens N. Renal actions of the selective angiotensin AT2 receptor ligands CGP 42112B and PD 123319 in the sodium depleted rat. Eur J Pharmacol 1993;249: 85-93.
158. MacFadyen RJ, Tree M, Lever AF, Reid JL. Responses to losartan (DuP753/MK954) infusion during cardiac catheterization in conscious salt deplete dogs. Clin Sci 1993;85(2):157-163.
159. Madhun ZT, Ernsberger P, Ke K C, et al. Signal transduction mediated by angiotensin II receptor subtypes expressed in rat renal mesangial cells. Regul Pept 1993;44:149-157.
160. Marie J, Maigret B, Joseph MP, et al. Tyr292 in the seventh transmembrane domain of the AT1A angiotensin II receptor is essential for its coupling to phospholipase C. J Biol Chem 1994;269:20815-20818.
161. Marrero MB, Schieffer B, Paxton WG, et al. Direct stimulation of JAK/STAT pathway by the angiotensin II AT1 receptor. Nature 1995;375:247-250.
162. Mayer G, Lafayette RA, Oliver J, Deen WM, Myers BD, Meyer TW. The effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993;43:346-353.
163. Mendelsohn FAO, Dunbar M, Allen A, et al. Angiotensin II receptors in the kidney. Fed Proc 1986;45: 1420-1425.
164. Millet D, Desgranges C, Campan M, Gadeau A, Costeronsu O. Effects of angiotensins on cellular hypertrophy and c fos expression in cultured arterial smooth muscle cells. Eur J Biochem 1992;206:367-372.
165. Mizuno K, Tani M, Niimura S, et al. Losartan a specific angiotensin II receptor antagonist increases angiotensin I and angiotensin II release from isolated rat hind legs: Evidence for locally regulated renin angiotensin system in vascular tissue. Life Sci 1992;50:209-214.
166. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem 1993;268:7338-7345.
167. Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76-82.
168. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven transmembrane receptors. J Biol Chem 1993;268: 24539-24542.
169. Murakami H, Liu JL, Zucker IH. Blockade of AT1 receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am J Physiol 1996;271:R303-309.
170. Murphy TI, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type 1 angiotensin II receptor. Nature 1991;351:233-236.
171. Nabika T, Velletri PA, Lovenberg W, Beaven MA. Increase in cytosolic calcium and phosphoinositide metabolism induced by angiotensin II and [Arg] vasopressin in vascular smooth muscle cells. J Biol Chem 1985;260:4661-4670.
172. Naftilan AJ, Zuo WM, Ingelfinger J, Ryan TJ, Jr Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest 1991;87:1300-1331.
173. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor Biochem Biophys Res Commun 1993;197:393-399.
174. Nakamura M, Misono KS, Naruse M, Workman RJ, Inagami T. A role for the adrenal renin angiotensin system in the regulation of potassium stimulated aldosterone production. Endocrinology 1985;117:1772-1778.
175. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP753 a new angiotensin II receptor antagonist in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335.
176. Nelson E, Merrill D, Sweet C, et al. Efficacy and safety of oral MK 954 (DuP753), an angiotensin receptor antagonist, in essential hypertension. J
177. Noda K, Saad Y, Kinoshita A, et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995;270:2284-2289.
178. Ohyama K, Yamano Y, Chaki S, Kondo T, Inagami T. Domains for G protein coupling in angiotensin II receptor type I: Studies by site directed mutagenesis. Biochem Biophys Res Commun 1992;189:677-683.
179. Parkinson CA, Belton SJ, Pratt JH. The effect of captopril treatment on potassium induced stimulation of aldosterone production in vitro. Endocrinology 1984;114:1567-1570.
180. Paxton WG, Marrero MB, Klein JD, Delafontaine P, Berk BC, Bernstein KE. The angiotensin II AT1 receptor is tyrosine and serine phosphorylated and can serve as a substrate for the src family of tyrosine kinases Biochem Biophys Res Commun 1994;200:260-267.
181. Peart WS. Evolution of renin. Hypertension (Suppl III) 1991;18(Suppl 5)III, 100-108.
182. Penit J, Faure M, Jard S. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture. Am J Physiol 1983;244:E72-E82.
183. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol 1987;49:413-435.
184. Phillips MT, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993;43:1-20.
185. Pucell AG, Hodges JC, Sen I, Bumpus FM, Husain A. Biochemical properties of the ovarian granulosa cell type 2 angiotensin II receptors. Endocrinology 1991;128:1947-1959.
186. Qadri F, Culman J, Veltmar A, Maas K, Rascher W, Unger T. Angiotensin II induced vasopressin release is mediated through alpha, adrenoreceptors and angiotensin II AT 1 receptors in the supraoptic nucleus. J Pharmacol Exp Ther 1993;267:567-574.
187. Quinn SJ, Enyedi P, Tillotson DL, Williams GH. Cytosolic calcium and aldosterone response patterns of rat adrenal glomerulosa cells stimulated by vasopressin: Comparison with angiotensin II. Endocrinology 1990;127:541-548.
188. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol 1988;50:409-426.
189. Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993;87:283-290.
190. Rao GN, Greindling K, Fredrickson RM, Sonenberg N, Alexander RW. Angiotensin II induces phosphorylation of eukaryotic protein synthesis initiation factor 4E in vascular smooth muscle cells. J Biol Chem 1994;269:7180-7184.
191. Rao RH. Pressor doses of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats. J Endocrinol 1996;148:311-318.
192. Reis LC, Saad WA, Camargo LA, Renzi A, Menani V, Silveira JE. Inhibitory effect of DUP 753 on the drinking responses of rats to central administration of noradrenaline and angiotensin II and to dehydration. Brazilian J Med Biol Res 1996;29:507-510.
193. Remuzzi A, Perico N, Amuchastegui CS, et al. Short and long term effects of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40-49.
194. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size selectivity in IgA nephropathy. Kidney Int 1991;39:1267-1273.
195. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G. Comparison of the effects of angiotensin converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 1996;4:19-25.
196. Ricard V, Ghaleh B, Berdeaux A, Giudicelli JF. Comparison of the effects of Exp3174 an angiotensin II antagonist and enalaprilat on myocardial infarct size in anesthetized dogs. Br J Pharmacol 1993;110(3): 969-974.
197. Rowland NE, Rozelle A, Riley PJ, Fregly MJ. Effect of nonpeptide angiotensin receptor antagonists on water intake and salt appetite in rats. Brain Res Bull 1992;29:389-393.
198. Ruff D, Gazdick LP, Berman R, Goldberg AI, Sweet CS. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. J Hypertens 1996;14:263-270.
199. Ruff D, Jamison S, Chen K, Cohen S. Induction fay EGF and interferon gamma of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. Science 1993;261:1733-1736.
200. Rutledge DA, Smith L, Smith JB. Angiotensin II increases cell calcium, stimulates amiloride inhibitable sodium entry and depolarizes cultured smooth muscle cells. Fed Proc 1985;44:459.
201. Saad WA, Luiz AC, Camargo LA, Renzi A, Menani JV. Losartan (DUP 753) blocks the natriuretic, kaliuretic and antidiuretic effect of intracerebroventricular injection of carbachol in water loaded rats. Brazilian J Med Biol Res 1996;29:511-513.
202. Saavedra JM, Correa FMA, Plunkett LM, Israel A, Kurihara M, Shigematsu K. Binding of angiotensin and atrial natriuretic peptide in brain of hypertensive rats. Nature 1986;320:758-760.
203. Saavedra JM, Israel A, Plunkett LM, Kurihara M, Shigematsu K, Correa FMA. Quantitative distribution of angiotensin II binding sites in rat brain by autoradiography. Peptides 1986;7:679-687.
204. Sasaki K, Yamamo Y, Bardham S, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin type 1 receptor. Nature 1991;351:230-232.
205. Schalekamp MA, Derkx FH, van den Meiracker AH. Renin inhibitors angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: Relationships between blood pressure responses and effects on the renin angiotensin system. J Hypertens 1992;10:S157-S164.
206. Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrano CM. Release of vasopressin from the rat hypothalamo neurohypophyseal system by the angiotensin 1, 7-heptapeptide. Proc Natl Acad Sci USA 1988;85:4095-4098.
207. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP. Renal effects of angiotensin I receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996;90:205-13.
208. Schor N, Ichikawa I, Brenner BM. Glomerular adaptations to chronic dietary salt restriction or excess. Am J Physiol 1980;238:F428-F436.
209. Schultz GS, Galardy RE, Jamieson JD. Biological activity of an angiotensin II ferritin conjugate on rabbit aortic smooth muscle cells. Biochemistry 1981;20:3412-3418.
210. Scoggins BA, Wright RD, Blair-West JR, Coghlan JP, Denton DA and Funder JW. The effect of the heptapeptide (2-8) and hexapeptide (3-8) fragments of angiotensin II on aldosterone secretion. J Clin Endocrinol Metab 1971;32(4):575-578.
211. Scott Burden T, Resink TJ, Baur U, Burgin M, Buhler FR. Activation of S6 kinase in cultured vascular smooth muscle cells by submitogenic levels of thrombospondin. Biochem Biophys Res Commun 1988; 150:278-286.
212. Semple PFA, Boyd AS, Dawes PM, Morton JJ. Angiotensin II and its heptapeptide (2 8) hexapeptide (3 8) and pentapeptide (4 8) metabolites in arterial and venous blood of man. Circ Res 1976;39:671-678.
213. Sernia C, Shinkel TA, Thomas WG, Ho KK, Lincoln D. Angiotensinogen secretion by single rat pituitary cells: Detection by a reverse haemolytic plaque assay and cell identification by immunocytochemistry. Neuroendocrinology 1992;55:308-316.
214. Shaw W, Snavely D, Shahinfar S. Safety and efficacy of losartan (DuP753 MK 954) in hypertensive patients with renal impairment. J Am Soc Nephrol 1994;5:567(abs).
215. Shea S, Cook EF, Kannel WB, Goldman L. Treatment of hypertension and its effect on cardiovascular risk factors: Data from the Framingham Heart Study. Circulation 1985;71:22-30.
216. Shier DN, Kusano E, Stoner GD, Franco Saenz R, Mulrow PJ. Production of renin angiotensin II and aldosterone by adrenal explant cultures: Response to potassium and converting enzyme inhibition. Endocrinology 1989;125:486-491.
217. Skeggs LT Jr. Discovery of the two angiotensin peptides and the angiotensin converting enzyme. Hypertension 1993;21:259-260.
218. Skorecki KL, Ballerman BJ, Hennke HJ, Brenner BM. Angiotensin receptor regulation in isolated renal glomeruli. Federation Proc 1983;42:3064-3070.
219. Sladek T, Sladkova J, Kolar F, Papousek F, Cicutti N, Korecky B, Rakusan K. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovas Res 1996;31:568-576.
220. Smith JB. Beta adrenergic stimulation inhibits calcium efflux and alters the morphology of cultured arterial muscle cells. J Cell Physiol 1984;121:375-382.
221. Smith JB. Angiotensin receptor signaling in cultured vascular smooth muscle cells. Am J Physiol 1986; 250:F759-F769.
222. Smith JB, Brock TA. Analysis of angiotensin stimulated sodium transport in cultured smooth muscle cells from rat aorta. J Cell Physiol 1983;114:284-290.
223. Smith JB, Smith L, Brown ER, et al. Angiotensin II rapidly increases phosphatidate phosphoinositide synthesis and phosphoinositide hydrolysis and mobilizes intracellular calcium in cultured arterial muscle cells. Proc Natl Acad Sci USA 1984;81:7812-7816.
224. Soffer BA, Wright JT, Jr Pratt JH, et al. Antihypertensive effect of combination therapy with losartan and hydrochlorothiazide in mild to severely hypertensive patients who are not adequately controlled on HCTZ alone. Am J Hypertens 1994;7:42A.
225. Soltis EE, Jewell AL, Dwoskin LP, Cassis LA. Acute and chronic effects of losartan (DuP753) on blood pressure and vascular reactivity in normotensive rats. Clin Exp Hypertens 1993;15:171-184.
226. Sowers JR, Epstein M. Diabetes mellitus and hypertension; emerging therapeutic perspectives. Cardiovasc Drug Rev 1995;13:149-210.
227. Steiner RW, Tucker BJ, Blantz RC. Glomerular hemodynamics in rats with chronic sodium depletion: Effect of saralasin. J Clin Invest 1979;64:503-512.
228. Streeten DHP, Anderson GH, Freiberg JM, Dalakos TG. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension. N Engl J Med 1975;292:657-662.
229. Sugimoto K, Gotoh E, Takasaki I, et al. AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt loaded Dahl salt sensitive rats. Clin Exp Pharmacol Physiol 1996;23:282-286.
230. Swales JD. The renin angiotensin system as a target for therapeutic intervention. J Cardiovasc Pharmacol Suppl 24 1994;2:S1-S5.
231. Sweet CS, Bradstreet DC, Berman RS, et al. Pharmacodynamic activity of intravenous E 3174 an angiotensin II antagonist in patients with essential hypertension. Am J Hypertension 1994;7:1035-1040.
232. Tabrizchi R, Pang CCY. Are angiotensin receptors in vascular smooth muscles a homogenous population? Eur J Pharmacol 1987;142:359-366.
233. Taddei S VA, Mattei P. Vascular renin angiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharm (Suppl 1) 1994;23:S9-S14.
234. Takahasi K, Bardhan S, Kambayashi Y, Shirai H, Inagami T. Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor AT2. Biochem Biophysic Res Commun 1994;198:60-66.
235. Tamaki T, Nishiyama A, Yoshida H, et al. Effects of EXP3174, a non peptide angiotensin II receptor antagonist on renal hemodynamics and renal function in dogs. Eur J Pharmacol 1993;236:15-21.
236. Taub KJ, Caldicott JHW, Hollenberg NK. Angiotensin antagonists with increased specificity for the renal vasculature. J Clin Invest 1977;59:528-535.
237. Taubman MB, Berk BC, Izumo S, et al. Angiotensin II induces c fos mRNA in aortic smooth muscle. J Biol Chem 1989;264:526-530.
238. The National High Blood Pressure Education Program Working Group. National high blood pressure group report on hypertension in diabetes. Hypertension 1994;23:145-158.
239. Timmermanns PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
240. Timmermans PBMWM, Carini DJ, Chiu AT, et al. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens 1991;4:275S-281S.
241. Timmermans PBMWM, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptor subtypes. Am J Hypertens 1992;5:406-410.
242. Timmermans PBMWM, Wong PC, Chiu AT, Smith RD. The preclinical basis of the therapeutic evaluation of losartan. J Hypertens (Suppl 1) 1995;13:S1-S13.
243. Tofovic SP, Pong AS, Jackson EK. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension 1991;18:774-782.
244. Torres VE, Northrup TE, Edwards RM, Shah SV, Dousa TP. Modulation of cyclic nucleotides in isolated rat glomeruli. J Clin Invest 1978;62:1334-1343.
245. Tsuda T, Alexander RW. Angiotensin II stimulates phosphorylation of nuclear lamins via a protein kinase C dependent mechanism in cultured vascular smooth muscle cells. J Biol Chem 1990;265:1165-1170.
246. Tsuda T, Kawahara Y, Ishida Y, Koide M, Shii K, Yokoyama M. Angiotensin II stimulates two myelin basic protein/microtubule associated protein 2 kinases in cultured vascular smooth muscle cells. Circ Res 1992;71:620-630.
247. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
248. Tsutsumi K, Saavedra JM. Characterization of AT2 angiotensin II receptors in rat anterior cerebral arteries. Am J Physiol 1991;261:H667-H670.
249. Tsutsumi K, Saavedra JM. Increased dithiothreitol insensitive type 2 angiotensin II receptors in selected brain areas of young rats. Cell Mol Neurobiol 1991;11:295-299.
250. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991;261:R209-216.
251. Tsutsumi K, Saavedra JM. Differential development of angiotensin II receptor subtypes in the rat brain. Endocrinology 1991;128:630-632.
252. Unger T, Gohlke P, Paul M, Rettig R. Tissue renin angiotensin systems: Fact or fiction? J Cardiovasc Pharmacol 1992;18:S20-S25.
253. Van der Bent V, Demole C, Johnson EI, et al. Angiotensin II induces changes in the cytosolic sodium concentration in bovine adrenal glomerulosa cells: Involvement in the activation of aldosterone biosynthesis. Endocrinology 1993;133:1213-1220.
254. van Kleef EM, Fingerle J, Daemen MJ. Angiotensin II induced progression of neointimal thickening in the balloon injured rat carotid artery is AT1 receptor mediated. Arteriosclerosis, Thromb Vasc Biol 1996;16: 857-863.
255. Wamsley JK, Herblin WF, Hunt M. Evidence for the presence of angiotensin II type 1 receptors in the brain. Brain Res Bull 1990;25:397-400.
256. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan: A preliminary report. Am J Hypertens 1992;5:247S-251S.
257. Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989;163:284-291.
258. Widdop RE GS, Kemp PA. Inhibition of the haemodynamic effects of angiotensin II in conscious rats by AT2 receptor antagonists given after the AT1 receptor antagonist EXP 3174. Br J Pharmacol 1992;107: 873-880.
259. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists: Studies with EXP9270 and DuP753. Hypertension 1990;15:823-834.
260. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. IV; EXP6155 and EXP6803. Hypertension 1989;13:489-497.
261. Wong PC, Price WA, Chiu AT, et al. In vivo pharmacology of DuP753. Am J Hypertens 1991;4:288S-298S.
262. Wong PC PW, Chiu AT. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:719-725.
263. Wood JM, Mah SC, Schnell C. Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition and angiotensin II antagonism in rats. J Cardiovasc Pharmacol (Suppl 4) 1990;16: S60-S64.
264. Xie MH, Liu FY, Wong PC, Timmermans PBMWM, Cogan MG. Proximal nephron and renal effects of DuP753 a nonpeptide angiotensin II receptor antagonist. Kidney Int 1990;38:473-479.
265. Yamano Y, Ohyama K, Kikyo M, et al. Mutagenesis and the molecular modeling of the rat angiotensin II receptor (AT1). J Biol Chem 1995;270:14024-4030.
266. Yazawa H Iida, Kubota E, Honda K. Human aortic smooth muscle cells containing angiotensin II type 1 receptors. Jpn J Pharmacol 1993;62:339-343.
267. + antiporter in vascular smooth muscle. Hypertension 1996;27:72-78.
268. Yonezawa T, Umemoto S, Fujii A, Katayama K, Matsuzaki M. Comparative effects of type 1 angiotensin II receptor blockade with angiotensin converting enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. J Cardiovasc Pharm 1996;27:119-124.
269. Yoshimura Y, Karube M, Aoki H, Oda T, Koyama N, Nagai A, Akimoto Y, Hirano H, Nakamura Y. Angiotensin II induces ovulation and oocyte maturation in rabbit ovaries via the AT2 receptor subtype. Endocrinology 1996;137:1204-1211.
270. Zhang J, Pfaffendorf M, Zhang JS, van Zwieten PA. A non-competitive type of angiotensin receptor antagonism by losartan in renal artery preparations. Eur J Pharmacol 1994;252:337-340.
271. Zhou J, Ernsberger P, Douglas JG. A novel angiotensin receptor subtype in rat mesangium: Coupling to adenylyl cyclase. Hypertension 1993;21:1035-1038.